Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Albumin-Related Ratios Investigated in HBV-Associated Decompensated Cirrhosis

By LabMedica International staff writers
Posted on 25 Mar 2022

Decompensated cirrhosis (DeCi) is a terminal liver disease characterized by various complications and associated with dramatically reduced survival. More...

Liver transplantation is the most effective therapy for hepatitis B virus (HBV)-DeCi.

Serum albumin is considered a biomarker of malnutrition–inflammation syndrome, and there is emerging data that hypoalbuminemia is related to worse survival in intensive care unit patients. Albumin has multiple functions and plays important roles in liver disease severity, progression, and prognosis.

Clinical Laboratorians at The Second Affiliated Hospital Zhejiang University (Zhengzhou, China) enrolled a total of 161 HBV-DeCi patients. The main causes of admission were ascites (n = 120, 74.5%), gastrointestinal bleeding (n = 36, 22.5%), hepatorenal syndrome (n = 22, 14.0%), and encephalopathy (n = 10, 6.2%). Twenty-four patients (15.0%) had more than one feature of decompensation at presentation.

Laboratory variables (total bilirubin, total protein, albumin, blood urea nitrogen [BUN], creatinine, aspartate aminotransferase, alanine aminotransferase, C-reactive protein [CRP], white blood count [WBC], platelet count, hemoglobin, neutrophil count, plasma D-dimer, and international normalized ratio [INR]), and HBV-DNA levels, as well as hepatitis B e antigen status, were recorded at admission. Severity of liver disease and prognosis were assessed using the Model for End-Stage Liver Disease (MELD) score.

The investigators reported that a total of 29 (18.0%) patients had died 30 days after admission. The prognostic roles of C-reactive protein-to-albumin ratio (CAR), D-dimer-to-albumin ratio (DAR), prothrombin time-international normalized ratio-to-albumin ratio (PTAR), neutrophil count-to-albumin (NAR), and blood urea nitrogen-to-albumin ratio (BAR) in HBV-DeCi were different. CAR, PTAR, NAR, and BAR were significantly higher in non-survivors compared with survivors. However, DAR did not differ between the two groups. The predictive power of BAR was superior to that of the other four albumin-related biomarkers and similar to that of MELD score. On multivariate analysis, BAR and MELD score were identified as independent prognostic factors, and the combination of BAR and MELD score may improve the prognostic accuracy in HBV-DeCi.

The authors concluded that they had evaluated five albumin-related ratios (CAR, DAR, PTAR, NAR, and BAR) for the prediction of mortality in HBV-DeCi patients. Their study suggests that BAR can be a simple, effective, and useful prognostic tool to predict poor outcomes in HBV-DeCi patients and that use of a combination of BAR and MELD score can improve the prognostic accuracy. The study was published on March 17, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
The Second Affiliated Hospital Zhejiang University 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The screening algorithm incorporates two plasma biomarkers: amyloid-beta ratio and p-tau217, which together help indicate brain amyloid burden (Image Credit: Shutterstock)

Algorithm Uses Blood Biomarkers to Improve Alzheimer’s Trial Screening

Alzheimer’s disease is a progressive neurodegenerative disorder that causes memory loss and functional decline. Screening cognitively healthy adults for prevention trials is slow and costly because many... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.